Conference call and webcast at 8:00 a.m. ET NEW YORK, March 27, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for ...
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the Company received a Refusal to File (RTF) letter from the U.S. Food and ...
Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is changing the ...
Overall, 82%, 11%, and 7% of speakers supported drug approval, opposed approval, and were neutral, respectively. (HealthDay News) — Most speakers attending US Food and Drug Administration (FDA) Human ...
Much is riding on Travere Therapeutics’ bid to gain an expansion for Filspari to treat focal segmental glomerulosclerosis ...
FDA leaders under President Donald Trump are moving to abandon a decades-old policy of asking outside experts to review drug applications, a move critics say would shield the agency’s decisions from ...
Biohaven said the U.S. Food and Drug Administration no longer plans to hold an advisory-committee meeting on the biopharmaceutical company's proposed troriluzole treatment for the rare genetic disease ...
The researchers found that 48% of speakers are patients and family members, 99% of whom support drug approval. HealthDay News — Most speakers attending US Food and Drug Administration (FDA) Human Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback